ABT
NYSE · Health Care
Abbott Laboratories
$107.25
-2.04 (-1.87%)
Financial Highlights (FY 2026)
Revenue
44.30B
Net Income
6.52B
Gross Margin
56.7%
Profit Margin
14.7%
Rev Growth
+0.5%
D/E Ratio
0.25
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 56.7% | 56.7% | 52.0% | 52.0% |
| Operating Margin | 18.2% | 16.4% | 23.6% | 26.7% |
| Profit Margin | 14.7% | 14.0% | 18.1% | 16.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 44.30B | 44.08B | 33.22B | 38.26B |
| Gross Profit | 25.10B | 24.97B | 17.29B | 19.91B |
| Operating Income | 8.05B | 7.21B | 7.86B | 10.21B |
| Net Income | 6.52B | 5.84B | 6.02B | 6.40B |
| Gross Margin | 56.7% | 56.7% | 52.0% | 52.0% |
| Operating Margin | 18.2% | 16.4% | 23.6% | 26.7% |
| Profit Margin | 14.7% | 14.0% | 18.1% | 16.7% |
| Rev Growth | +0.5% | +0.5% | +10.5% | -2.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 19.08B | 19.08B | 25.40B | 31.10B |
| Total Equity | 76.94B | 76.94B | 104.22B | 116.10B |
| D/E Ratio | 0.25 | 0.25 | 0.24 | 0.27 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 9.73B | 9.20B | 10.39B | 11.25B |
| Free Cash Flow | — | — | 6.26B | 6.35B |